JUPITER NEUROSCIENCES, INC. (JUNS) — SEC Filings

Latest SEC filings for JUPITER NEUROSCIENCES, INC. (JUNS), explained in plain English.

Sentiment Overview: 1 bearish, 25 neutral

Recent Filings (26)

• Jupiter Neurosciences Files 2025 10-K, Signals Year-End Performance — 10-K · 2026-04-01T16:45:31-04:00 [neutral] Risk: medium
  JUPITER NEUROSCIENCES, INC. (JUNS) filed its annual 10-K report with the SEC on April 1, 2026, covering the fiscal year ended December 31, 2025. As a Delaware-i
• 8-K Filing — 8-K · 2025-12-23T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-12-22T00:00:00.000Z [neutral]
• S-1 Filing — S-1 · 2025-11-26T00:00:00.000Z [neutral]
• 8-K/A Filing — 8-K/A · 2025-11-20T00:00:00.000Z [neutral]
• 10-Q Filing — 10-Q · 2025-11-14T00:00:00.000Z [neutral]
• DEFA14A Filing — DEFA14A · 2025-11-07T00:00:00.000Z [neutral]
• DEF 14A Filing — DEF 14A · 2025-11-06T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-10-27T00:00:00.000Z [neutral]
• Jupiter Neurosciences Files Q2 2025 10-Q — 10-Q · 2025-08-19T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the company
• Jupiter Neurosciences Files 8-K — 8-K · 2025-07-10T00:00:00.000Z [neutral] Risk: low
  Jupiter Neurosciences, Inc. filed an 8-K on July 10, 2025, reporting other events and financial statements and exhibits. The filing does not contain specific fi
• Jupiter Neurosciences Announces Board and Executive Changes — 8-K · 2025-07-09T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. announced on July 2, 2025, changes in its board and executive team, including the election of new directors and the appointment of c
• Jupiter Neurosciences Files Q1 2025 10-Q — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: low
  Jupiter Neurosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Jupiter Orphan Therapeutics, Inc., i
• Jupiter Neurosciences Changes Auditors — 8-K · 2025-04-21T00:00:00.000Z [neutral] Risk: low
  Jupiter Neurosciences, Inc. announced on April 16, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered pu
• 10-K Filing — 10-K · 2025-03-28T00:00:00.000Z [neutral]
• Jupiter Neurosciences Faces Delisting Concerns — 8-K · 2025-03-25T00:00:00.000Z [bearish] Risk: high
  Jupiter Neurosciences, Inc. filed an 8-K on March 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The comp
• Jupiter Neurosciences Files Q3 10-Q — 10-Q · 2024-12-23T00:00:00.000Z [neutral] Risk: low
  Jupiter Neurosciences, Inc. filed its Q3 10-Q report on December 23, 2024, for the period ending September 30, 2024. The company, formerly Jupiter Orphan Therap
• Jupiter Neurosciences Appoints New Directors, CEO & CSO — 8-K · 2024-12-20T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. announced on December 17, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two
• Jupiter Neurosciences Files 8-K: Material Agreement Announced — 8-K · 2024-12-19T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. announced on December 15, 2024, that it entered into a Material Definitive Agreement. The company also filed financial statements an
• Jupiter Neurosciences Files 8-K: Material Agreement — 8-K · 2024-12-04T00:00:00.000Z [neutral] Risk: medium
  On December 2, 2024, Jupiter Neurosciences, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financ
• Jupiter Neurosciences Files 8-K on Material Agreement — 8-K · 2024-11-19T00:00:00.000Z [neutral] Risk: medium
  On November 15, 2024, Jupiter Neurosciences, Inc. entered into a material definitive agreement, likely a financing or debt arrangement, as indicated by the fili
• Alexander Rosén Files SC 13D for Jupiter Neurosciences — SC 13D · 2024-11-15T00:00:00.000Z [neutral] Risk: medium
  On November 8, 2024, Alexander Rosén filed a Schedule 13D for Jupiter Neurosciences, Inc. This filing indicates a change in beneficial ownership of the company'
• Jupiter Neurosciences Files S-1/A Amendment — S-1/A · 2024-10-18T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. filed a Pre-Effective Amendment No. 22 to its Form S-1 Registration Statement on October 18, 2024. This filing, under Registration N
• Jupiter Neurosciences Files S-1/A Amendment — S-1/A · 2024-09-13T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. filed a Pre-Effective Amendment No. 21 to its Form S-1 Registration Statement on September 13, 2024. The company, formerly known as
• Jupiter Neurosciences Files S-1/A Amendment — S-1/A · 2024-09-04T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. filed a Pre-Effective Amendment No. 19 to its Form S-1 Registration Statement on September 3, 2024. This filing relates to the regis
• Jupiter Neurosciences Files S-1/A Amendment — S-1/A · 2024-07-12T00:00:00.000Z [neutral] Risk: medium
  Jupiter Neurosciences, Inc. filed a Pre-Effective Amendment No. 18 to its Form S-1 Registration Statement on July 12, 2024. The company, incorporated in Delawar